Directional migration of leukocytes: Their pathological roles in inflammation and strategies for development of anti-inflammatory therapies

Cell Research

Volumn 11, Issue 2, 2001, Pages 85-88

  Geng, Jian Guo ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Directional cell migration; Inflammation; Leukocytes; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOCYTE MIGRATION INHIBITION FACTOR;

ANIMAL; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; HEPARIN; HUMANS; INFLAMMATION; LEUKOCYTE MIGRATION-INHIBITORY FACTORS; LEUKOCYTES; NF-KAPPA B;

EID: 0035375198     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290071     Document Type: Review

References (28)

1. McCutcheon M. Chemotaxis in leukocytes. Physiol Rev 1946; 26:319-36.
2. Hynes RO, Lander AD. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 1992; 68:303-22.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-14.
4. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67:1033-6.
5. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994; 45:361-78.
6. Geng J-G. Platelet and endothelial cell P-selectin and its leukocyte sialoglycoprotein ligand. Trends Glycosci Glycotech 1995; 7:333-42.
7. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79:181-13.
8. Downey GP. Mechanisms of leukocyte motility and chemotaxis. Curr Opin Immunol 1994; 6:113-24.
9. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-8.
10. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436-45.
11. Jung S, Littman DR. Chemokine receptors in lymphoid organ homeostasis. Curr Opin Immunol 1999; 11:319-25.
12. Melchers F, Rolink AG, Schaneil C. The role of chemokines in regulating cell migration during humoral immune responses. Cell 1999; 99:351-4.
13. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286:2098-102.
14. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-41.
15. Geng J-G, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343:757-60.
16. 2+-induced conformational change in the lectin domain of GMP-140. J Biol Chem 1991; 266:22313-8.
17. 2+ ions. J Biol Chem 1992; 267:19846-53.
18. Ma L, Raycroft L, Asa D, Anderson DC, Geng J-G. A sialoglycoprotein from human leukocytes functions as a ligand for P-selectin. J Biol Chem 1994; 269:27739-46.
19. Asa D, Raycroft L, Ma L, Aeed PA, Kaytes PS, Elhammer ÅP, Geng J-G. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. J Biol Chem 1995; 270:11662-11670.
20. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8:49-64.
21. Ahmed T, Campo C, Abraham MK, Molinari JF, Abraham WM, Ashkin D, Syriste T, Andersson LO, Svahn CM, Ahmed T. Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness and mast cell degranulation by a non-anticoagulant heparin: comparison with low-molecular weight heparin. Am J Respir Crit Care Med 1997; 155:1848-55.
22. Teixeira MM, Rossi AG, Hellewell PG. Adhesion mechanisms involved in C5a-induced eosinophil homotypic aggregation. J Leukocyte Biol 1996; 59:389-96.
23. Webb LMC, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin-8. Proc Natl Acad Sci USA 1993; 90:7158-60.
24. Thourani VH, Brar SS, Kennedy TP, Thornton LR, Watts JA, Ronson, RS, Zhao Z.-Q, Sturrock AL, Hoidal JR, Vinten-Johansen J. Nonanticoagulant heparin inhibits NF-κB activation and attenuates myocardial reperfusion injury. Am J Physiol 2000; 48: H2084-93.
25. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang Y-N, Sitzmann JV, Hannan RL. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 1999; 99:1062-68.
26. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995; 9:899-909.
27. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol 2000; 12:85-98.
28. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.